Design Cloud

  • Home

  • About Us

    Company Profile HIstory Culture Honor
    • Company Profile

    • HIstory

    • Culture

    • Honor

  • Products

    Cardiovascular series Psychiatry series Hepatobiliary, Gastroenterology Series Respiratory series Anti-infective virus series Other series Large Infusion Series Huabao Tong Series Active Pharmaceutical Ingredient Series
    • Cardiovascular series

    • Psychiatry series

    • Hepatobiliary, Gastroenterology Series

    • Respiratory series

    • Anti-infective virus series

    • Other series

    • Large Infusion Series

    • Huabao Tong Series

    • Active Pharmaceutical Ingredient Series

  • R&D

    Academician Expert Workstation Medical Research and Industry Alliance
    • Academician Expert Workstation

    • Medical Research and Industry Alliance

  • News

    General News Party group dynamics Employee activity
    • General News

    • Party group dynamics

    • Employee activity

  • HR

    Talent Strategy Company recruitment
    • Talent Strategy

    • Company recruitment

  • Contact us

  • 中文版

Image Name

News

  • Home page

General News

Party group dynamics

Employee activity

Environmental Announcement for Wanbangde Pharmaceutical Group's Annual Production Project of 2,195 Tons of Active Pharmaceutical Ingredients (including 12 products such as 600 tons/year of lipoic acid)

Date:

17 Jan,2023


Previous page

Industry-Education Integration and School-Enterprise Collaboration | Wanbangde Pharmaceutical Group Successfully Selected for the "2021–2022 Zhejiang Province Industry-Education Integrated Enterprise" List!

Honors | Wanbangde Pharmaceutical Group Named Among Top 500 High-Tech Enterprises in Zhejiang Province for Innovation Capability!

Next page

Related Recommendations

Image Name

2025/01/21

Good News | Wanbangde Pharmaceutical Group's WP103 (Huperzine A Injection) Receives U.S. FDA Approval for Clinical Trials

Image Name

2025/01/21

Good News | Wanbangde Pharmaceutical Group’s WP107 (Huperzine A Oral Solution) Receives U.S. FDA Approval for Clinical Trials

Image Name

2025/01/13

Good News | Wanbangde Pharmaceutical Group's Cefaclor Granules Pass Consistency Evaluation!

< 1234...78 > proceed page
  • Home

  • About Us

    • Company Profile

    • HIstory

    • Culture

    • Honor

  • Products

    • Cardiovascular series

    • Psychiatry series

    • Hepatobiliary, Gastroenterology Series

    • Respiratory series

    • Anti-infective virus series

    • Other series

    • Large Infusion Series

    • Huabao Tong Series

    • Active Pharmaceutical Ingredient Series

  • R&D

    • Academician Expert Workstation

    • Medical Research and Industry Alliance

  • News

    • General News

    • Party group dynamics

    • Employee activity

  • HR

    • Talent Strategy

    • Company recruitment

  • Contact us

  • 中文版

Image Name

Website Development: China Enterprise DynamicsTaizhou

Business license
浙ICP备10002622号-38